Technology for Enhanced Vaccine Development
- Technology Benefits
- Identification of novel peptides that will initiate robust protective immune responses to microorganisms and parasites like tuberculosis, listeria, malaria, and many othersUses the cells own machinery to generate the antigenic MHC II restricted peptides
- Technology Application
- vaccine development
- Detailed Technology Description
- Very little is known about the experimental or therapeutic regulation of antigenic peptide occupancy of major histocompatibility (MHC) molecules, particularly in the case of the MHC class II molecules. The opportunity to regulate MHC antigenic peptide occupancy with small molecules could greatly increase our ability to identify peptides that can occupy the MHC binding clefts and thereby interact efficiently with T-cells for initiating effective, robust immune responses.To this end, USF Researchers have developed a novel process that utilizes histone deacetylase inhibitors (HDACIΓÇÖs). Data demonstrate that HDACIΓÇÖs can regulate HLA-DR peptide occupancy. The treatment with HDACIΓÇÖs alters the peptidome of cells by regulating components of the MHC II class antigen processing machinery.This technology can be utilized to identify novel immunogenic MHCII peptides that can be used for general or personalized vaccination strategies involving pathogen or tumor proteins.
- *Abstract
-
The University of South Florida has developed a novel process for identifying and generating novel immunogenic peptides that may lead to enhanced vaccine opportunities. This has implications for vaccines directed against microorganisms, parasites, and potentially even cancer vaccines.
- Country/Region
- USA
For more information, please click Here
